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ABSTRACT
Muscle fructose 1,6-bisphosphatase (FBP2), besides being a regulatory enzyme 
of glyconeogenesis also protects mitochondria against calcium stress and plays a 
key role in regulation of the cell cycle, promoting cardiomyocytes survival. However, 
in cancer cells, FBP2 acts as an anti-oncogenic/anti-proliferative protein. Here, we 
show that the physiological function of FBP2 depends both on its level of expression 
in a cell as well as its oligomerization state. Animal fructose-1,6-bisphosphatases 
are thought to function as tetramers. We present evidence that FBP2 exists in an 
equilibrium between tetramers and dimers. The dimeric form is fully active and 
insensitive to AMP, the main allosteric inhibitor of FBP2. Tetramerization induces the 
sensitivity of the protein to AMP, but it requires the presence of a hydrophobic central 
region in which leucine 190 plays a crucial role. Only the tetrameric form of FBP2 is 
retained in cardiomyocyte cell nucleus whereas only the dimeric form associates with 
mitochondria and protects them against stress stimuli, such as elevated calcium and 
H2O2 level. Remarkably, in hypoxic conditions, which are typical for many cancers, 
FBP2 ceases to interact with mitochondria and loses its pro-survival potential. Our 
results throw new light on the basis of the diverse role of FBP2 in cells.
INTRODUCTION
Fructose 1,6-bisphosphatase (FBP), a regulatory 
gluconeogenic enzyme, was shown to have functions far 
exceeding regulation of glucose/glycogen synthesis. It 
participates in cardiac mitochondria protection against 
calcium stress [1–2]. It also plays a role in regulation of 
the cell cycle – it is transported into the nucleus in the late 
G1 phase and accumulates there through the S and G2 
phases both in cardiomyocytes and in cancer cells. Nuclear 
FBP appears to promote cell survival, as withdrawal of the 
protein from the nucleus correlates with increased mortality 
of cardiomyocytes [3–7]. On the other hand, it was also 
shown that FBP acts as an anti-oncogenic protein both by its 
enzymatic, “anti-glycolytic” activity and by an interaction 
with HIF-1, a master glycolysis activator and that in some 
cancers, FBP is depleted [8–13].
While the pro-proliferative and stress-protective 
action of FBP is associated with the muscle isoform 
(FBP2), the anti-oncogenic function seems to be common 
for both the isoforms: FBP2 and FBP1 (the liver isoform). 
Thus, it seems that FBP promotes both survival and 
mortality of a cell. Factors determining which of these two 
contradictory effects are dominant remain unknown and 
this apparent paradox remains unresolved.
In the present paper, we present evidence that the 
pro-survival role of FBP2 is dependent on the enzyme’s 
quaternary structure.
Mammalian FBP has been previously described as 
a solely tetrameric protein, composed of two identical 
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dimers, so called upper and lower dimer. Depending on 
a relative orientation of the dimers, the tetramer can 
exist in an active R-state or an inactive T-state. The 
switch between R- and T-state is caused by binding 
of AMP, the enzyme’s most potent allosteric inhibitor 
[14–21].
Here, we show that in the absence of allosteric 
effectors (AMP and NAD+), only about half of the total 
FBP2 species are tetramers and significant amounts of 
dimers and monomers exist in the solution. Addition of 
AMP induces almost complete tetramerization of the 
wild-type FBP2 (WT FBP2) even at submicromolar AMP 
concentrations. A dimer-tetramer equilibrium has never 
been demonstrated before for any of the two mammalian 
isoforms of FBP nor was the presence of free monomers 
shown for any FBP.
Crystal structures of human muscle FBP2 in the R- 
and T-states presented in our previous study highlighted 
residues D187 and L190 as potentially necessary for 
existence of the R-state tetramer [21]. Here, we show that 
the tetramerization is disrupted partially by D187L and 
completely by L190G substitution. Such recombinant 
dimeric FBP2 forms retain catalytic activity. However, 
their sensitivity to AMP is decreased and in contrast 
to the WT FBP2, the mutants oligomerization state is 
unaffected (L190G) or only slightly affected (D187L) by 
increasing AMP concentrations. The classical model of 
FBP2 inhibition by AMP assumes that binding of AMP 
to the allosteric site of one subunit in an FBP dimer 
stabilizes the so-called catalytic loop belonging to a 
subunit in the adjacent dimer in its inactive conformation 
[22–23]. Results of our newest kinetic experiments 
suggest that in high concentrations of AMP, there is 
an alternative mechanism of FBP2 inhibition by this 
compound.
In our previous papers, we have shown that 
the quaternary structure of FBP2 influences not only 
its enzymatic activity, but also the ability to bind to 
mitochondria and that saturation of FBP2 with AMP 
prevents binding of the enzyme to these organelles [2]. We 
have also characterized physiological factors required to 
stimulate nuclear transport of FBP2 [6] and identified the 
functional Nuclear Localization Sequence (NLS) within 
the FBP2 structure [5].
Here, we show that both nuclear and mitochondrial 
roles of FBP2 are strictly related to its oligomerization 
state. We show that only the dimeric FBP2 can interact 
with mitochondria and protect them against stress stimuli, 
however, unexpectedly, FBP2 loses its pro-survival 
potential in hypoxic conditions. On the other hand, only 
the tetrameric form is retained in the nuclei. This striking 
difference of function between two oligomeric forms of 
the same enzyme offers new, exciting possibilities. It can 
be envisioned that modulation of the oligomerization state 
of FBP2 could enable switching its action from promotion 
of cell survival to induction of death.
RESULTS & DISCUSSION
FBP2 promotes cell survival under oxidative 
stress but impairs it under hypoxic conditions
Previously, we have shown that in HL-1 cells with 
down-regulated FBP2 (the FBP2- cells), the mitochondria 
are more susceptible to stress-induced depolarization [1]. 
Subsequently, we constructed the HL-1 cell line with 
overexpression of FBP2 (the FBP2+ cells). PCR analysis 
demonstrated that the ratio of FBP2 mRNA in the HL-1 
FBP2-, wild-type (WT) and FBP2+ cells was 0.28 : 1 : 
1.71. More importantly, these differences were also visible 
at the protein level (see Supplementary Figure 1). Using 
the MTT assay we found that under control conditions, 
the viability of the FBP2+ cells was about 1.4-time higher 
than WT (p=0.02) and about 2-times higher than FBP2- 
cells (p<0.001).
Then, we compared cellular ROS production 
and mitochondrial polarization under stress induced by 
hyperoxic conditions (H2O2) in cells with the different 
levels of FBP2 expression. It turned out that cellular ROS 
production was inversely proportional while mitochondrial 
polarization was directly proportional to the level of 
FBP2 expression (Figure 1). Results of the MTT assay 
revealed that under the H2O2 treatment the FBP2+ cells 
were, respectively, almost 1.9- and 3.7-times more viable 
than WT and FBP2- cells. Importantly our pilot study 
on the mouse lung squamous cell carcinoma line (KLN-
205) demonstrated that such protection against ROS 
might be a common mechanism as the KLN-205 cells 
overexpressing FBP2 were, respectively, about 1.25- and 
3.1-times more viable than WT and FBP2- KLN-205 cells 
(see Supplementary Figure 2). Thereafter, we checked 
viability of the HL-1 cells under hypoxic conditions. In 
such conditions, we observed a reverse trend and now 
the FBP2- cells were about 1.7- and 4-times more viable 
(p<0.05) than WT and FBP2+ cells, respectively. Taken 
together, these results show that FBP2 overexpression 
increases the HL-1 cells growth and/or survival in 
normoxia and under hyperoxic conditions but impairs it 
in hypoxia.
D187L and L190G mutations disrupt AMP 
inhibition of FBP2
To resolve the FBP2 structure-function relationship 
we substituted residues D187 and L190, which were 
indicated by crystallographic studies as potentially 
important for proper quaternary structure of FBP2 [21], 
with leucine and glycine residues, respectively. All 
the FBP2 forms were purified to homogeneity (purity 
>95%). We then investigated a general biochemical 
characteristics of the mutants, their interaction with cell 
nuclei and mitochondria, and their role in regulation of 
cell survival. As AMP is the most important regulator 
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of FBP2 quaternary structure [21, 24] we looked for 
differences in its effect on the kinetics of the WT FBP2 
and the mutants. To that end, we first established that the 
D187L and L190G mutants retained enzymatic activity 
similar to the WT FBP, although they required, three- and 
two-times higher Mg2+ concentration for maximal activity, 
respectively. Table 1 summarizes kinetic parameters of 
fructose-1,6-bisphosphate (F-1,6-BP) hydrolysis reaction, 
activation by Mg2+ and inhibition by AMP for D187L and 
L190G mutants compared with the WT FBP2 and WT 
FBP1. Figure 2 shows a comparison of AMP inhibition 
curves for WT, D187L and L190G FBP2.
The effect of L190G substitution on AMP inhibition 
was striking. The inhibition became biphasic, with the first 
half maximal inhibition constant (IC50) of 84.4±6.73 μM 
which is more than 140-fold higher than that of the WT 
FBP2. The IC50 for the second phase of the inhibition was 
23.3±2.52 mM – about one thousand times higher than 
physiological concentration of AMP in mammalian tissues 
[25]. The effect of D187L mutation was less pronounced. 
The IC50 constant for D187L FBP2 was 1.44±0.06 μM, 
about 2.5-fold higher than that of the WT FBP2 but still 
about 3.5-times lower than IC50 of WT FBP1. However, 
the maximal observed inhibition of D187L mutant was 
about 80%, compared to about 95%, which was observed 
for the WT FBP2. Cooperativity of AMP binding was 
retained in both mutants, although the second phase of 
L190G FBP2 inhibition had a lower Hill coefficient (n; 
1.68±0.25) as compared to n~2.0 which was observed for 
all other FBP forms. These results show that both D187 
and L190 residues play role in the mechanism of inhibition 
of FBP2 by AMP and that the L190 residue was critical for 
this inhibition.
Residues D187 and L190 are indispensable for 
proper quaternary structure and oligomerization 
of FBP2
To test the effect of the introduced mutations 
on FBP2 quaternary structure, specifically its 
oligomerization state, we performed sedimentation 
velocity analytical ultracentrifugation (SV) experiments 
with the WT, D187L and L190G FBP2 mutants in the 
presence and absence of AMP. In the initial experiment, 
we used various concentrations of FBP2 variants: 0.1, 
0.5 and 1 mg/ml. As concentration of the proteins had 
no effect on their oligomerization (see Supplementary 
Figure 3), the next experiments were performed at 
0.5 mg/ml. Figure 3 demonstrates the relative amount 
of various oligomeric states of the WT FBP2 and 
the mutants at the different concentrations of AMP. 
Normalized signal intensity versus sedimentation 
Figure 1: Comparison of the sensitivity of HL-1 cells with different levels of FBP2 expression to oxidative stress (H2O2). 
(A, B). Production of ROS in control conditions (A) and under H2O2 (B) – dihydrofluorescein diacetate staining; (C, D). Polarization of 
mitochondrial network in control conditions (C) and under H2O2 (D) – JC-1 staining. Bar = 10 μm.
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coefficient graphs and SV experiment data can be found 
in the supplementary material (Supplementary Figure 3 
and Supplementary Table 1).
To our surprise, we observed that in the absence of 
AMP, only about half of the WT FBP2 was tetrameric, 
while about 30% was dimeric and 15% monomeric. The 
results for FBP2 mutants were even more intriguing. 
Both mutants existed primarily as dimers – 83.4% for 
D187L and 91.2% for L190G. Clearly, both D187 and 
L190 residues are key for stability of the tetrameric 
form of FBP2. Furthermore, the oligomeric states of 
both mutants upon addition of AMP differed profoundly 
from the WT FBP2. At AMP concentration as low as 
0.16μM, which is lower than the IC50 reported here for 
the WT FBP2 and lies in the low end of the range of 
previously reported IC50 values [20, 26–27], WT FBP2 
was predominantly tetrameric and remained so at higher 
AMP concentrations (120 μM and 5 mM). However, the 
mutants proved much more resistant to AMP-induced 
tetramerization. The L190G FBP2 remained dimeric 
at all analyzed AMP concentrations (from 0 up to 5 
mM). The D187L FBP2 showed no tetramerization at 
0.16 μM AMP, but was in about a 45% tetrameric state 
at 120 μM AMP and 35% tetrameric at 5 mM AMP. 
Figure 2: AMP inhibition of wild-type and mutant FBP2. Activity is presented as a fraction of FBPase activity in the absence 
of inhibitor. Curves were fitted to experimental data points as described in the materials and methods section. At least 3 independent 
measurements were performed for each AMP concentration.
Table 1: Kinetic parameters of mutant and wild-type forms of FBP1 and FBP2
kcat [s




n, F-1,6-BP a A50[mM], 
Mg2+
n, Mg2+ IC50, AMP 
[μM] a
n, AMP a
FBP2 WT 20.9±2.52 3.66±0.07 111±2.3 1.61±0.04 0.88±0.05 1.96±0.21 0.59±0.01 2.04±0.05
FBP2 D187L 15.3±0.56 12.9±0.64 120±12 1.72±0.05 3.22±0.23 2.05±0.27 1.44±0.06 2.29±0.21
FBP2 L190G 23.8±3.19 5.82±0.20 119±3.6 1.99±0.06 1.96±0.09 1.94±0.17 84.4±6.7323300±2520
2.06±0.33
1.68±0.25
FBP1 b 16.7±0.5 2.2±0.4 157±48 1 0.31±0.01 1.93±0.12 5.06±0.27 1.95±0.16
Data presented as mean±SD
a – determined at Mg2+ concentration of 5 mM for wild-type FBP2, 15 mM for D187L mutant and 10 mM for L190G 
mutant.
b – as described in [20].
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This undermines the traditionally held view that FBP is 
a strictly tetrameric enzyme and confirms the hypothesis 
based on crystallographic and kinetic studies that residues 
D187 and L190 are indispensable for the allosteric 
inhibition by AMP. Both the residues were thought to be 
crucial for forming interactions between the dimers, so 
called “leucine lock”, which stabilizes the active cross-
like tetrameric form of the enzyme (R-state). However, the 
mechanism presented here differs significantly from the 
canonical model which assumes that dissociation of AMP 
from the flat (“slab-like”) inactive FBP2 tetramer induces 
rotation towards the active cross-like R-structure [21, 24]. 
We demonstrate that in the absence of allosteric inhibitors, 
FBP2 exists in an equilibrium of monomeric, dimeric and 
tetrameric forms. Remarkably, the dimeric structure of 
muscle FBP is sufficient to support catalysis: the entirely 
dimeric L190G FBP2 was fully catalytically-active. AMP 
and, presumably, NAD+, induces tetramerization of the 
enzyme which then exists in an equilibrium of R and 
T-state tetramers (NAD+ was shown to inhibit FBP2 in 
the same manner as AMP, however, the IC50 was about 
250 times higher than in the case of AMP [26]). Contrary 
to what was assumed so far, the switch between T and R 
states does not necessarily involve rotation of the upper 
and lower dimers but may be achieved through their 
exchange between tetramers. Such continuous assembly 
and disassembly of FBP2 tetramers would require at 
least a part of FBP2 molecules to exist as dimers at any 
given time. This is in agreement with the experimental 
evidence: WT FBP2 dimers (as well as monomers) were 
detected even at 5mM concentration of AMP. A similar 
phenomenon of subunit exchange was reported earlier for 
FBP1, however, unlike here, it was completely abolished 
in the presence of AMP [28]. These results make a case for 
“dimer exchange” rather than “dimer rotation” explanation 
of the R-to-T-state switch of FBP2. Both models are 
schematically presented in Figure 4.
FBP from E. coli has also been demonstrated to 
be dimeric. However, in contrast to the mammalian 
enzyme, tetramerization activates the E. coli enzyme. 
Moreover, tetramerization is caused by citrate or 
phosphoenolpyruvate (PEP) and not AMP. The binding 
site of citrate and PEP is not conserved between E. coli 
and mammalian FBP, despite high-level conservation of 
the overall fold [29]. Clearly, the mechanism described 
here must have evolved after the separation of mammalian 
and bacterial lineages.
Based on the kinetic results, we also propose the 
existence of an additional mechanism of FBP2 inhibition 
by AMP, different from the classical one which assumes 
that binding of AMP induces the T-state tetramer 
formation, where the catalytic loops of 52-72 are stabilized 
in the inactive conformation [22–23]. Since the L190G 
FBP2 was inhibited by high concentrations of AMP even 
though it was almost completely dimeric thus, evidently, 
AMP caused FBP2 inhibition based only on structural 
changes within the dimer.
Since the classic AMP binding sites were not 
affected by the mutations, the observed inhibition of the 
mutants suggests the presence of the second AMP binding 
site within the FBP2 subunit. It may be presumed that in 
high AMP concentration, the inhibitor may associate with 
the active site and inhibit the activity non-allosterically. 
The active sites within the dimer may communicate with 
each other as they are formed by residues belonging to 
both subunits (residue R243 participates in F-1,6-BP 
Figure 3: Oligomerization of wild-type and mutant FBP2 in increasing concentrations of AMP. Data is presented as 
percentage of different oligomeric forms in total population of FBP2, determined by analytical centrifugation with interferometric detection.
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binding in the adjacent monomer within the dimer) [21, 
30], and hence the cooperative signal may be transmitted 
between them. Such mechanism of cooperativity is in 
line with the results of our study on F-1,6-BP hydrolysis, 
which demonstrated the cooperativity of the reaction, with 
n between 1.6 and 2 for all studied FBP2 forms.
Mutant and WT FBP2 have a similar effect on 
cell survival in hypoxia and reoxygenation
To check the effect of introduced mutations on cell 
survival, we transfected cardiomyocytes with partially 
silenced FBP2 expression (the FBP2- cells) with the 
WT, D187L and L190G FBP2 protein. After overnight 
incubation with various FBP2 forms, the cells were 
divided into three groups which were cultured in one of 
the following conditions: 4 hours of normoxia (control), 4 
hours of hypoxia, or 3 hours of hypoxia and subsequently 
1 hour of normoxia (reoxygenation experiment). Cells 
were then harvested and the number of viable cells 
determined using capillary flow cytometry (Figure 5). 
In normoxia, the number of cells transfected with WT 
FBP2 was higher than the number of untransfected 
FBP2- cells. Differences between cells transfected 
with both the mutants and untransfected cells were not 
statistically significant. However, in hypoxia, the number 
of untransfected FBP2- cells was significantly higher 
than the number of cells transfected with any form of 
FBP2. These results are consistent with data presented 
earlier demonstrating that FBP2 silencing impairs cell 
growth in normoxia but increases survival in hypoxia. In 
the reoxygenation experiment, there were no statistically 
Figure 4: Schematic representation of different FBP2 R- to T-state transition models. (A) “Dimer rotation” model. (B) 
“Dimer exchange” model. Note that the two models are not mutually exclusive.
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Figure 5: Viability of HL1 FBP2- cells after transfection with FBP2 in hypoxia and reoxygenation. Data is presented 
as mean number of cells normalized to FBP2- cells in control conditions (n=3 culture wells). Error bars represent standard 
deviation. * - statistical significance with p-value of 0.033 vs FBP2-, 0.0033 vs FBP2 D187L, and 0.011 vs FBP2 L190G. 
** - statistical significance with p-value of 5.7×10-5 vs FBP2 WT, 6.8×10-5 vs FBP2 D187L, and 8.8×10-4 vs FBP2 L190G. 
p-values were obtained using Student’s T-test.
Figure 6: Nuclear localization of WT and L190G FBP2 in control conditions and after the nuclear export blockade 
with Leptomycin B. (A) WT FBP2 (predominately tetrameric); (B) L190G FBP2 (dimeric form). Bar = 10 μm.
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significant differences between any of the groups, 
however, the number of cells transfected with D187L and 
L190G was slightly higher than the other two groups and 
the number of D187L- and L190G-transfected cells in 
hypoxia.
Oligomerization state of FBP2 determines its 
subcellular localization
It has been previously shown that the subcellular 
localization of FBP2 depends on extracellular signals [1, 
6] and the cell cycle phase [7]. In HL-1 cardiomyocytes, 
FBP2 may be homogeneously distributed in cytoplasm, 
actively transported to nucleus, or interact with 
mitochondria. Results of our previous studies revealed 
that the physiological role of FBP2 in the organelles is not 
restricted to its catalytic activity. This raises a question 
whether the subcellular localization, and thus, function of 
the enzyme depends on its oligomerization state. To test 
this, first we checked the subcellular distribution of the 
FBP2 mutants.
HL-1 cells were transfected with FITC-conjugated 
WT and mutant FBP2. As a result, nuclear localization 
of FBP2 was observed in about 50% of HL-1 cells 
transfected with the WT protein, but only in about 6.6 and 
8% of cells incubated with the D187L and L190G mutant, 
respectively. Moreover, the fluorescent signal from the 
nuclei of cells transfected with either of the mutants never 
achieved as high intensity as the signal from nuclei of WT 
protein transfected cells (Figure 6). Owing to the fact that 
both the mutants were shown to exist primarily as dimers, 
it could be assumed that only the tetrameric form of FBP2 
was able to pass through the nuclear pore. This, in turn, 
might suggest that the dimeric and monomeric forms 
were not recognized by importins. It is known that some 
proteins (e.g. transcription factor STAT) redistribute from 
cytoplasm to nucleus following oligomerization because 
in monomers, NLS of these proteins exists in an inactive 
state [31]. But in the case of FBP2, it seemed unlikely that 
the tetramerization process was required for the functional 
appearance of the NLS [5]. More conceivably, it hindered 
interactions of FBP2 with nuclear export machinery.
It has been shown that nuclear export of p53 is 
regulated by the leucine-rich nuclear export signal (NES) 
located in its tetramerization domain [32]. Although the 
analysis of FBP2 sequence assigned a low probability of 
the presence of NES in the protein sequence, we found 
that the hydrophobic cluster comprised of residues 
LGEFVL (190-195) may function as a putative NES. In 
the quaternary structure, these residues are located on the 
interface of upper and lower dimers, thus they might be 
inaccessible to CRM1 protein (exportin 1), necessary for 
the withdrawal of FBP2 from HL-1 cells’ nuclei [6, 21].
To test this hypothesis, we repeated the transfection 
procedure in the presence of Leptomycin B, an inhibitor 
of CRM1- and NES-dependent nuclear export. It 
appeared that FBP2 mutants could be trapped in nuclei 
by Leptomycin B (Figure 6). This suggests that a prompt 
export of the dimers was responsible for their mainly 
cytoplasmic localization, and that tetramerization of 
FBP2 masks, while dissociation into dimers unmasks the 
protein’s NES signal peptide.
In contrast to nucleo-cytoplasmic shuttling, there 
was no visible difference between the WT FBP2 and the 
mutants in their capability to interact with mitochondria 
(Figure 7). This was reflected by the calculated Manders’ 
overlap coefficient (M1), which was in the range of 0.8 for 
all the tested proteins. However, increasing concentrations 
of AMP (up to 500μM) introduced to all of the steps of the 
transfection procedure led to a drastic reduction of the WT 
FBP2 potential to interact with the organelles (M1=0.26), 
without any prominent effect on the D187L and L190G 
mutants (M1=0.71 and 0.8, respectively). Since the 
mutants were shown to withstand the AMP-induced 
tetramerization, it could be inferred that FBP2 binds to 
mitochondria mainly, if not solely, as a dimer.
Previously, we have demonstrated that FBP2 
protects mitochondria against high calcium-induced stress 
[1–2]. Thus, to investigate whether the apparent differences 
in mitochondria interaction abilities are reflected by 
disparity in protective potential of the FBP2 WT and 
mutants, we introduced the proteins into HL-1 FBP2- 
cells in the presence of AMP and tested susceptibility of 
the mitochondria to Ca2+-induced depolarization. As we 
have shown before [1], mitochondria of the FBP2- cells 
were susceptible to depolarization and the cells were prone 
to detachment from the substrate and clustering (Figure 
8A). Transfection of the cells with the FBP2 WT reduced 
the cells’ tendency to detach (which might be a result of 
a nuclear action of the protein) under the Ca2+ treatment 
but has no marked effect on mitochondria (Figure 8B). 
Introduction of D187L and L190G mutants increased 
mitochondrial polarization (Figure 8C). Collectively, these 
results show that FBP2 dimers but not tetramers exert the 
protective effect on mitochondria. It is also worth to note 
that, in contrast to high Ca2+ and H2O2, hypoxic conditions 
did not induce FBP2-mitochondria interaction (data not 
shown).
Our data shed new light on FBP2 quaternary 
structure and its regulation by small-molecule ligands. 
We demonstrated that two different FBP2 non-metabolic 
functions – one connected to the nuclear localization and 
the other to interaction with mitochondria – are strictly 
dependent on its oligomerization state and probably 
mutually exclusive. This discovery was made possible 
thanks to the utilization of the unique features of the 
D187L and L190G mutants, the first FBP2 mutants 
disrupting the oligomerization of the enzyme.
The precise mechanism governing the partition 
of FBP2 population between its roles in the cytoplasm, 
nucleus and mitochondria is still unclear. The main factor 
deciding whether FBP2 activity, both metabolic and non-
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Figure 8: Changes in mitochondrial polarization after transfection of the HL-1 FBP2- cells with different forms of 
FBP2 in the presence of 0.5 mM AMP. (A) FBP2- cells, non-transfected; (B) FBP2- cells transfected with WT FBP2; (C) FBP2- cells 
transfected with L190G FBP2. Bar = 10 μm.
Figure 7: Co-localization of FBP2 forms (green) with mitochondria (gray) in HL-1 cardiomyocytes. (A) wild-type FBP2 
in control conditions; (B) L190G mutant in control conditions; (C) wild-type FBP2 in the presence of 0.5 mM AMP; (D) L190G mutant in 
the presence of 0.5 mM AMP. Nuclei are counterstained with DAPI. Bar = 5 μm.
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metabolic, promotes cellular death or survival appears to 
be the availability of oxygen and different energy sources. 
In cells growing under normoxic conditions or utilizing 
non-carbohydrate energy sources, FBP2 is required for 
growth, survival and cell cycle progression. This is in line 
with our previous studies [4, 6–7] and studies on metastatic 
cancer cells [33]. However, under hypoxic conditions, 
typical for many malignant cancers, FBP2 ceases to play 
the protective role. In such conditions, silencing of the 
enzyme promotes cell survival. This agrees with studies 
showing that in cancer cells, FBP levels are frequently 
reduced and their overexpression under hypoxia reduces 
the level of hypoxia-inducible factor-1 α (HIF-1α) protein 
[9]. HIF-1α is a transcription factor that not only regulates 
glucose metabolism but also induces angiogenesis and 
thus, helps cancer cells overcome hypoxic conditions. 
Therefore, FBP-dependent decrease of HIF-1α inhibits 
cancer growth, migration and survival [9].
Since in hypoxic conditions, FBP2 does not interact 
with mitochondria, it could be hypothesized that hypoxia 
changes the cellular FBP2 dimer-tetramer balance towards 
tetramer and the tetramer impedes cellular growth and 
survival by hindering HIF-1α expression. Thus, it appears 
that modulation of the oligomerization state of FBP2 in 
a cell by low molecular weight compounds could enable 




Human FBP2 mutants D187L and L190G were 
created from tag-free WT FBP2 carried on pETite plasmid 
(Lucigen) with GENEART Site-Directed Mutagenesis 
kit (Invitrogen) and WALK DNA Polymerase (A&A 
Biotechnology) using standard protocols provided by 
the manufacturer. The following primer pairs were used: 
D187L FW: 5’-GAC CTC TTC ATG CTT CTG CCG 
GCT CTT GGT GAA-3’, D187L RV: 5’-TTC ACC AAG 
AGC CGG CAG AAG CAT GAA GAG GTC-3’, L190G 
FW: 5’-ATG CTT GAC CCG GCT GGT GGT GAA 
TTT GTC CT-3’, L190G RV: 5’-AGG ACA AAT TCA 
CCA CCA GCC GGG TCA AGC AT-3’. Sequences were 
confirmed by DNA sequencing using T7 promoter and T7 
terminator primers.
Protein expression and isolation
All muteins of FBP2 were expressed in E. coli 
and purified according to the following protocol. Clonal 
colonies of Hi-control BL21(DE3) cells (Lucigen) 
carrying pETite vectors with inserts encoding tag-free 
FBP2 were grown on agar-LB (A&A Biotechnology) 
plates with 30 μg/ml kanamycin (Sigma). Randomly 
selected clones were used to inoculate 3 ml LB pre-
culture and incubated overnight in a shaker incubator set 
to 37°C, 200 RPM. 500 ml of LB was inoculated with 
2 ml of the pre-culture and grown in 37°C, 180 RPM 
for 5 h. Expression of FBP2 was induced by addition of 
IPTG (A&A Biotechnology) to a final concentration of 
100 μg/ml. Proteins were expressed overnight. Cells were 
pelleted by centrifugation at 4000xg, 10 min, 4°C. and 
lysed using BugBuster (MERCK). Cellular debris was 
removed by centrifugation at 17,000 x g, 25 min, 4°C. 
Two steps of out-salting were preformed using 50% and 
75% saturation of ammonium sulfate. FBP2-containing 
precipitant was dissolved in 25mM TRIS-HCl buffer, pH 
7.5 and dialyzed against the buffer. The protein solution 
was then incubated with cellulose phosphate (Sigma) 
at pH 7.1 for 1 h and loaded on 10ml Pierce Centrifuge 
Columns (ThermoFisher Scientific). The column bed was 
repeatedly washed with 25 mM TRIS-HCl buffer pH 7.0, 
1500 x g, until no absorption peak at 280 nm wavelength 
could be seen in spectrum of the flowthrough. FBP2 was 
eluted with 20 mM phosphate buffer, pH 8.0 containing 20 
mM fructose-1,6-bisphosphate (F1,6P2, Sigma). Purity of 
isolated FBP2 was checked using SDS-PAGE.
Enzyme activity measurement
Measurements of FBP2 activity were conducted at 
pH 7.5 and 37°C using a glucose 6-phosphate isomerase—
glucose 6-phosphate dehydrogenase coupled assay. 
The reduction of NADP+ to NADPH was monitored 
spectrophotometrically at 340 nm [24]. Parameters were 
estimated in MATLAB’s curve fitting tool using nonlinear 
least squares regression with trust-region algorithm and 
bisquare robust fitting. For assay of FBP2 activation 
by Mg2+ and inhibition by AMP at least triplicate 
measurement was done for each concentration of a ligand. 
Data on inhibition by AMP was fitted to the following 
equations of monophasic (eq. 1) and biphasic (eq. 2) 
modes of inhibition:
( )[ ] [ ]= − +v / v 1 I * I / IC I (1)max max n 50n n  (1)
( )
( )
[ ] [ ]
[ ] [ ]
= − +
− +
v / v 1 I * I / IC I










Where: v – observed reaction rate, vmax – reaction 
rate in the absence of inhibitor, Imax – maximal inhibition, 
[I] – inhibitor concentration, IC50 – half-maximal inhibition 
constant, n – Hill coefficient, Imax1 – maximal inhibition of 
the first phase, Imax2 – maximal inhibition of the second 
phase, IC50low – half-maximal inhibition constant of the 
first phase, IC50high – half-maximal inhibition constant of 
the second phase, n1 – Hill constant of the first phase, 
n2 – Hill coefficient of the second phase. Parameters of 
fructose-1,6-bisphosphate hydrolysis were calculated from 
estimations based on three independent reactions.
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Sedimentation velocity analytical 
ultracentrifugation
The sedimentation velocity analytical ultra-
centrifugation experiments (SV) were conducted in a 
Beckman Coulter ProteomeLab XL-I ultracentrifuge 
(software version 6.0, Beckman Coulter Inc., Brea, CA, 
USA). An-60 Ti rotor and cells with two-channel charcoal 
filled Epon® centerpieces and sapphire windows were 
used. The sample sector was filled with 400 μl of solution 
of FBP2 or its mutant, the reference sector contained 400 
μl of appropriate buffer. The protein concentrations were 
0.1, 0.5 and 1 mg/ml for proteins without AMP and 0.5 mg/
ml for proteins with AMP. The experiment was conducted 
overnight at 42,000 rpm at 20°C. Sedimentation was 
monitored by laser interferometry.
Time-corrected [34] scans representing the whole 
sedimentation process were analyzed using SEDFIT 
software (http://www.analyticalultracentrifugation.
com). The density and dynamic viscosity of the buffer, 
as well as partial specific volumes of FBP2 variants were 
estimated using SEDNTERP (http://www.jphilo.mailway.
com/download.htm) [35]. For wild type FBP2 and the 
L190G mutant, sedimentation coefficients (s), frictional 
ratios (f/f0) and apparent molecular weights (MWapp) were 
calculated using the continuous c(s) distribution model 
with 10 points per 1 S. In the case of the D187L mutant, 
the parameters were calculated using c(s) distribution 
with bimodal f/f0 model. 200 logarithmically distributed 
sedimentation coefficient values in the range of 1-100 
S were fitted to the data. This allowed us to mitigate 
the influence of high MW aggregates (>15 S) on the 
analysis. Maximum entropy regularization with p=0.68 
was applied [36]. The quality of the fits was assessed 
using RMSD values, residual distributions and residual 
histograms.
Protein labelling
Proteins were dialyzed against borate buffer, pH 
9.2 and mixed with FITC (Sigma) dissolved in 50% 
DMSO to a protein:FITC molar ratio of 1:40. The 
mixture was incubated in 4°C overnight and then dialyzed 
against PBS. Protein concentration and number of FITC 
molecules per FPB2 monomer were then measured 
spectrophotometrically [5].
Cell culture
The murine Hl-1 cardiomyocytes, a gift from prof. 
W.C. Claycomb (Louisiana State University Health 
Science Center, New Orleans, LA, USA), who first 
established and characterized the cell line [37], were 
cultured as described in [6].
A lentiviral cocktail of five shRNAs targeted to 
mouse FBP2 (Mission shRNA Lentiviral Transduction 
Particles, Sigma, cat no. NM_007994) was used to down-
regulate the gene [1] and the pCMV6-FBP2 plasmid was 
used to achieve the overexpression of FBP2 in HL-1 cells. 
The level of FBP2 mRNA was analyzed by PCR as it 
was described in [7]. The PCR products were subjected 
to agarose gel electrophoresis with ethidium bromide 
staining and the density of the gel bands was quantified 
using the GeneTools v4.0 (Syngene) program.
To roughly assay the amount of FBP2 protein present 
in homogenates from the HL-1 cells differing in FBP2 
expression protein samples were resolved by SDS-PAGE 
(40 μg of homogenate proteins per lane), with the use of 
purified FBP2 as the mass marker. FBP2 was detected using 
Western blotting as described in [1], except that luminol 
was used as the peroxidase substrate. The antibodies against 
FBP were tested before on numerous cells and tissues [e.g. 
1, 3-4], and proved to be specific against the protein.
Protein delivery to HL-1 cells and confocal 
microscopy
FBP2 was delivered into cells using CHARIOT 
Protein Delivery Reagent (Active Motif). For cytometric 
analyses, 1.14 μl (2.28 μg) of CHARIOT and 0.3 μg of 
FBP2 per well in 24-well plates were mixed and applied 
on cells in the serum-free Claycomb medium according to 
the manufacturer’s protocol. After 2 h of incubation with 
the protein delivery mixture, the cells were supplemented 
with medium containing serum (to the final serum 
concentration of 6%). No FBP2 was added to control 
samples. Cells were then cultured overnight. The next 
day, the protein delivery medium was exchanged with 
the full culture medium. In experiments with AMP, all 
the used media were supplemented with AMP to a final 
concentration of 500 μM. The cells were then cultured as 
described in the section below.
For fluorescence imaging experiments, cells 
growing on coverslips in 12-well plates were transfected 
with 0.5 or 1.5 μg of FITC-conjugated WT FBP2 or the 
mutants a described above, and grown in the full culture 
medium for additional 24 h before fixing and staining. The 
higher amount of FBP2 was shown to ensure relatively 
fast accumulation of the protein inside the nucleus [5] 
whereas the lower amount facilitated observation of 
changes in the FBP2 interaction with mitochondrial 
network. To visualize mitochondria, cells were stained 
with 500nM MitoTracker® Deep Red FM (ThermoFisher 
Scientific) in growth medium for 30 min and then fixed 
in 4% paraformaldehyde. The coverslips were mounted 
on microscopic slides in Fluoroshield with DAPI (Sigma).
Images were acquired on FV-1000 confocal 
microscope (Olympus) with 60x (oil, Plan SApo, 
NA=1.35) objective. The fluorochromes were excited at 
405 (DAPI), 473 (FITC) and 635 (MitoTracker® Deep Red 
FM) nm and imaged using the Sequential scan option.
To quantify the FBP2-mitochondria co-localization, 
after subtraction of background from the images, Manders’ 
overlap coefficient M1 was calculated using the ImageJ 
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1.47v software and the JACoP plugin [38]. M1 can be 
concisely defined as the proportion of a signal from the 
green channel (FBP2-FITC) that overlaps with a signal 
from the red channel (Mitotracker). Its values can vary 
from 0 to 1, where the former means no overlap of images 
and the latter corresponds to 100% co-localization of two 
images [35]. The non-paired Student’s t-test was used for 
comparisons between two experimental groups.
Cytometric measurements of HL-1 FBP2- cells 
viability after hypoxia and reoxygentaion
The HL-1 FBP2- cells, which have the expression 
of FBP2 reduced to about one-fourth of the normal level, 
were seeded in 24-well plates at a density of 50, 000 cells/
cm2. Three wells were used for each delivered protein 
and growth condition. After overnight culture, cells were 
transfected as described above. Next, the control plate was 
incubated in air containing 5% CO2 and the two remaining 
plates in the hypoxic atmosphere of 95% N2, 5% CO2 in 
the Brinkubator MIC-101 hypoxic chamber (Billups-
rothenberg). After 3 h, one of the plates in hypoxic 
conditions was transferred to air with 5% CO2 with 
cover removed to improve ventilation, while the other 
remained in 95% N2, 5% CO2. All plates were incubated 
for another hour. Then, cells were thoroughly detached 
from wells using trypsin, pelleted, and suspended in the 
culture medium. The cell suspensions were diluted 10- 
fold in Guava ViaCount reagent (Merck) and incubated 
in RT for 10 min, following manufacturer’s guidelines. 
The number and viability of cells were measured using 
Guava easyCyte flow cytometer (Merck). For each sample 
two measurements of 1000 events were taken. Events 
were categorized as viable cells, dead cells, and debris by 
EasyFit algorithm of GuavaSoft 2.7 ViaCount software. 
The non-paired Student’s t-test was used for comparisons 
between experimental groups.
Measurement of mitochondrial polarization and 
ROS production
Live cells were examined with the Olympus IX71 
fluorescence microscope equipped with the Cell^F 
software (Olympus).
Loss of the mitochondrial membrane potential 
was detected using JC-1 fluorescent dye (Mitochondrial 
Permeability Transition Detection Kit, AbD Serotec) 
according to the manufacturer’s instruction. Polarized 
mitochondria accumulate more of the dye and are red. In 
cells with depolarized mitochondria, most of the dye is 
dispersed in cytoplasm and has green fluorescence. The 
ratio of red to green fluorescence reflects the degree of 
the mitochondrial membrane polarization. The JC-1 
dye was excited at 488 nm for 500 ms and the emission 
was observed using a long pass filter, which allowed 
for simultaneous observation of green (monomers) and 
red (aggregates) fluorescence. For better discrimination 
between JC1 aggregates and monomers, the red 
fluorescence of the aggregates was presented as magenta 
in the pictures.
To measure intracellular ROS production the cells 
were loaded with 5 μM dihydrofluorescein diacetate 
(DHF; 20 min, 37°C), thoroughly rinsed with Hank’s 
Balanced Salt Solution, and mounted on slides. The 
fluorescence of the dye was excited at 488 nm for 
500 ms.
MTT assay
The HL-1 cells were seeded into 96-well plates 
(2x103 cells/well) and cultured for 24 and 96 h. Then the 
MTT assay was performed as described [39]. To test the 
effect of the oxidative stress and hypoxic conditions, the 
cells were treated with 0.25 mM H2O2 for 2 h (a fresh 
portion of H2O2 was added after 1 h of incubation) or were 
incubated in the hypoxic chamber as described above, 
before the MTT assay.
The absorbance was measured at 560 nm with 
a reference filter of 670 nm using a plate reader ASYS 
UVM340 (Biogenet). For the cells with different 
expression of FBP2, the number of respective viable 
cells obtained after 24 h culture in control conditions 
was assumed to be 1. In all experimental conditions, 
measurements were averaged from at least eight wells.
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